Varian, Inc. Reports Fourth Quarter 20...(items (1) - (3) above. (5) $4891 on ...),Health

Date:11/4/2009

items (1) - (3) above. (5) $4,891 on an adjusted basis excluding the tax impact of the adjustments described in items (1) - (3) above. (6) $11,528 and $0.40 per diluted share, respectively, on an adjusted basis excluding the adjustments (net of related tax effects) described in items (1) - (3) above. (7) $154,076 on an adjusted basis excluding $1,663 in acquisition- related intangible amortization, $172 in acquisition-related inventory write-up amortization and $466 in restructuring and other related costs. (8) $74,239 on an adjusted basis excluding $586 in acquisition-related intangible amortization and $273 in restructuring and other related costs. (9) $17,420 on an adjusted basis excluding $501 in restructuring and other related costs. (10) $0 on an adjusted basis excluding $215 related to an acquisition- related in-process research and development charge. (11) $36,735 on an adjusted basis excluding the adjustments described in items (7) - (10) above. (12) $14,417 on an adjusted basis excluding the tax impact of the adjustments described in items (7) - (9) above. (13) $22,978 and $0.78 per diluted share, respectively, on an adjusted basis excluding the adjustments (net of related tax effects) described in items (7) - (10) above.

                  VARIAN, INC. AND SUBSIDIARY COMPANIES
            UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF EARNINGS
                 (In thousands, except per share amounts)
                 Full Year FY 2009 and Full Year FY 2008

                                                   Fiscal Year Ended
                                                --------------------------
                                                October 2,      October 3,
                                                   2009           2008
                                     
'/>"/>
SOURCE  Varian, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
Related medicine technology :

1. Varian, Inc. to Release Fourth Quarter and Full Fiscal Year 2009 Financial Results
2. Varian, Inc. Delivers a Productivity Increase of Up to 100% With Its 710-ES Series ICP-OES
3. 96-Well Filtration Plate From Varian, Inc. Improves Sensitivity and Precision for Trace Bio-Analysis by LC/MS
4. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
5. Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate Update
6. Cambrex Reports Third Quarter 2009 Results
7. Regeneron Reports Third Quarter 2009 Financial and Operating Results
8. Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
9. Uroplasty Reports Results for Second Quarter FY2010
10. Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD
11. Mettler-Toledo International Inc. Reports Third Quarter 2009 Results